{
  "id": 16114748,
  "title": "Anixa Biosciences CEO Amit Kumar buys $21,760 in stock",
  "url": "https://urgent.news/2026/10/22/anixa-biosciences-ceo-amit-kumar-buys-21-760-in-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-22T22:16:01.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/anixa-biosciences-ceo-amit-kumar-buys-21760-in-stock-93CH-4967741"
  },
  "original_language": "en",
  "account": "Anixa Biosciences CEO Amit Kumar increased his stake in the company by purchasing 8,000 shares on October 22, 2026. The transaction, valued at $21,760, occurred at a stock price of $2.72 per share. Kumar now owns a total of 680,000 shares. Despite the stock's significant decline of 31% over the past year, analysts suggest the shares are overvalued, with price targets ranging from $6 to $14. Anixa Biosciences maintains a robust balance sheet with more cash than debt and a current ratio of 8.54, although profitability is not expected for this year. Recent developments include a positive response in a Phase 1 trial for a CAR-T cell therapy in recurrent ovarian cancer, and a patent granted for their breast cancer vaccine technology in Australia.",
  "summary": null,
  "key_points": [
    "Anixa CEO Amit Kumar bought 8,000 shares for $21,760 on October 22, 2026.",
    "Kumar now owns 680,000 shares of Anixa Biosciences.",
    "Despite a 31% stock decline, analysts view shares as potentially overvalued."
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}